Regeneron Pharmaceuticals
✦ Quant Fair Value how this is computed
- Implied fair-value range of 512.61-1,008.96, from this stock's own trailing 5-year average P/E applied to trailing EPS.
- Current price is +21.0% above the average-multiple fair value of 760.78.
Valuation each multiple against its own 5-year range
Vs. peers Biotechnology
| Company | Market cap | P/E (TTM)i | P/Bi | Div yieldi |
|---|---|---|---|---|
| Regeneron Pharmaceuticals (REGN) | 95.24B | 20.35 | 2.84 | 0.40% |
| Vertex Pharmaceuticals (VRTX) | 130.58B | 33.14 | 6.25 | 0.00% |
| Moderna (MRNA) | 78.90B | -27.70 | 11.54 | 0.00% |
| argenx SE (ARGX) | 58.21B | 32.06 | 6.92 | 0.00% |
| BeiGene (ONC) | 44.66B | 49.74 | 7.67 | 0.00% |
| Revolution Medicines (RVMD) | 34.87B | -17.66 | 14.52 | 0.00% |
Other StockVane-tracked companies in the same industry.
Morningstar
Trading 4.4% above Morningstar's fair value estimate.
Analyst note
Third quarter revenue grew 36% year over year, with net product sales growing 14% and total collaboration revenue growing 52%. Non-GAAP EPS rose 70%. Shares closed up 13% from the previous day's close on this news.
Why it matters: This result exceeded our expectations and was driven by the 68% year-on-year increase in Sanofi collaboration revenue. This line rose $1.1 billion, or 81% of the firm's $1.36 billion total revenue growth. Global sales of Dupixent (immunology), which are booked by Sanofi, grew 35%. Sanofi collaboration revenue, which is mostly profit-sharing on Dupixent sales, benefited not only from Dupixent's growth but also from a 7.8-point step-up as a percentage of relevant product sales from the prior-year period in collaboration revenue, thanks to the paydown of the development balance. US Eylea franchise (ophthalmology) sales declined only 1% this quarter, as growth in Eylea HD mostly offset a decline in Eylea original dose. This suggests declines have moderated, and we expect a roughly flat sequential change for the fourth quarter, or 2% year-over-year growth.
The bottom line: Both the step-up in Sanofi collaboration revenue and stabilization of the US Eylea franchise are high-quality drivers, and we are raising our fair value estimate for narrow-moat Regeneron to $880 from $730 to reflect greater near-term collaboration revenue from Dupixent sales. We now view shares as fairly valued.
Coming up: The US regulatory action date for cemdisiran's application in generalized myasthenia gravis, a rare autoimmune disease, is in November 2026. Despite stiff competition, this C5-targeting siRNA has blockbuster potential if it can carve out a meaningful position with its once-quarterly dosing schedule. Regeneron hopes to receive US approval for Eylea HD's prefilled syringe by the end of the year, which should drive further adoption.
Fair value
We are raising our fair value estimate to $880 per share from $730 to reflect greater near-term collaboration revenue from Dupixent sales.
We forecast the Eylea franchise to undergo double-digit declines in 2026 due to competitive pressures from Pavblu, Amgen's biosimilar version of low-dose Eylea, and Vabysmo, Roche's long-acting product that competes with Eylea HD.
The majority of our fair value estimate is driven by our expectations for the Eylea and Dupixent franchises. In our model, US sales booked by Regeneron for the Eylea franchise peaked in 2024 at $6 billion. We forecast Eylea HD will reach over $4 billion in peak sales, while low-dose Eylea undergoes steep declines consistent with biosimilar competition.
We assume Dupixent's global sales will peak at just under $30 billion. The drug's US composition of matter patent expires in March 2031, but Sanofi and Regeneron believe their patent thicket will extend its exclusivity period beyond this.
The firm's pipeline has always been an important pillar of the company's story. We model over $5 billion of revenue from newly launched drugs and pipeline assets, including Ordspono (B-cell lymphomas), Lynozyfic (multiple myeloma), cemdisiran (rare diseases, ophthalmology), the Factor XI program (anticoagulants), olatorepatide (obesity), and others.
We still see a potential headwind for Eylea sales from recent Centers for Medicare & Medicaid Services guidelines for Medicare negotiation included in the Inflation Reduction Act, which imply that high-dose Eylea could be eligible for negotiation in 2028, rather than protected by patents and exclusivity at least until the mid-2030s.
We assume a weighted average cost of capital of 7.3%.
Economic moat
We assign a narrow Morningstar Economic Moat Rating to Regeneron based on the intangible assets that underlie the commercial potential of its Eylea franchise (including low-dose Eylea and high-dose Eylea HD) and the productivity of its monoclonal antibody research and development platform, which has led to blockbuster sales of the immunology drug Dupixent. We think the firm does face environmental, social, and governance risks, particularly related to US drug price-related policy changes (most of Regeneron's revenue comes from the US market) and ongoing potential for product governance issues (including litigation). While we have factored these threats into our analysis, we don't see them as material to our valuation or moat rating.
Eylea, or aflibercept, had global sales of $7.9 billion in 2025, thanks to its strong competitive positioning and more attractive dosing regimen versus Lucentis and Avastin in ophthalmology indications. While low-dose Eylea loses US patent protection in 2027, a high-dose version, Eylea HD, launched in late 2023 with patent protection through 2039, allowing continued strong cash flows in ophthalmology despite new branded competition from Roche's Vabysmo.
Dupixent, or dupilumab, is poised to achieve peak sales of just under $30 billion ahead of potential Medicare negotiation in 2030 and the March 2031 expiration of its US composition of matter patent, as the drug continues to gain approvals in more immunology indications. It is an IL-4Ra inhibitor that blocks IL-4 and IL-13 signaling, which is implicated in certain allergic diseases. Its differentiated mechanism of action and solid safety profile have made it difficult for competitors to gain traction. In addition to key indications of asthma and atopic dermatitis, the drug was approved in the US in September 2024 for chronic obstructive pulmonary disease, another chronic disease with a large patient population. Sanofi and Regeneron believe that Dupixent's patent thicket will protect its exclusivity beyond 2031, although the precise timeline for loss of exclusivity remains unclear.
The company has an extremely full earlier-stage pipeline that its mAb research partnership with Sanofi partly supported, although the collaboration has been scaled back to focus on a handful of programs. Among oncology drugs, PD-1 antibody Libtayo is at the center and is seeing solid growth (albeit from a smaller base) in niche indications as well as lung cancer. Regeneron is testing Libtayo in combination with LAG-3 antibody fianlimab in melanoma and lung cancer and also in combination with various bispecific antibodies. While safety issues have delayed development of some of Regeneron's bispecifics, the firm continues to advance. Lynozyfic (linvoseltamab), a BCMA T-cell engager for treating multiple myeloma patients, received approvals in 2025.
Bull case
Eylea HD is one of the leading franchises in wet AMD and other ophthalmology markets, with Roche's Vabysmo as its main competitor.
Dupixent has solid launches in atopic dermatitis, asthma, chronic obstructive pulmonary disease, and various other immunology indications.
Regeneron has a robust pipeline spanning immunology, oncology, dermatology, rare disease, and cardiometabolic disease.
Bear case
Regeneron's pending application for US approval of Eylea HD's prefilled syringe is important for its market share.
While Regeneron's Praluent has entered the multibillion-dollar cholesterol-lowering market, it faces stiff competition from Amgen's Repatha and Novartis' Leqvio.
Although Regeneron has an excellent track record of innovation and has multiple potential blockbusters in late-stage development, these drug candidates are not yet derisked.
By Jay Lee
Quote time 2026-11-20 20:02:42 · For reference only, not investment advice and not tailored to your situation.
Regeneron Pharmaceuticals discussion 0 comments